VIDEO: Directional deep brain stimulation: novel treatment options for all Parkinson’s patients
sponsored by Boston Scientific
Author: SPONSOREDPublished: 4 October 2017
Prep: Cook: Serves:
Watch deep brain stimulation (DBS) experts Professor Pollo, Professor Timmermann, Professor Visser-Vanderwalle and Professor Volkmann explain the benefits of novel directional DBS systems for improved symptom control and fewer side effects
Every human brain is unique and every course of Parkinson’s disease has its own characteristics. In deep brain stimulation (DBS) therapy, physicians aim to target a very specific part of the brain – the subthalamic nucleus – in order to mitigate Parkinson’s symptoms.
Up until now, conventional DBS systems only allowed for stimulation with ring electrodes. With these electrodes, stimulation took the form of a ring around the electrode in the lead that was implanted into the patient’s brain. This meant that while physicians tried to target a very specific area of the brain, they always ran the risk of stimulating its neighbouring regions – since they could not steer the stimulation precisely. Unintended and unwanted stimulation could cause side effects such as speech problems.
The latest generation of DBS devices allow physicians to precisely steer the stimulation to target one specific area of the brain – significantly reducing side effects from unwanted stimulation. Our directional DBS systems use novel lead designs with segmented electrodes that allow the activation of individual electrode contacts. In addition, the technology in the pulse generator that powers the leads – the Multiple Independent Current Control (MICC) technology – allows the physician to specify exactly the amount of current needed for every contact of the electrode.
Through activating specific electrode contacts, and defining the amount of stimulation for each contact, stimulation precision is significantly increased. It is similar to shining a light on a specific spot with a flashlight. With the new systems, physicians now have full control of the stimulation steering and an increased set of stimulation options.
About deep brain stimulation (DBS) therapy
DBS uses a stimulator that is implanted into the patient’s chest. The stimulator sends mild electrical impulses to specific areas of the brain via thin wires called leads. This stimulation may help improve day-to-day experiences for people living with movement disorders such as Parkinson’s disease, dystonia, or essential tremor.
For comprehensive information on deep brain stimulation and Parkinson’s, please visit the EPDA website.
This article is sponsored by Boston Scientific. The information in this article is given for information purposes only and does not represent an endorsement by the EPDA of any particular treatments, products or companies. This article is not a substitute for advice from your doctor, pharmacist or other healthcare professional. Parkinson’s Life makes no representations or warranties of any kind, express or implied, about the completeness or accuracy of information provided.
“We want the world to walk with us,” says Parkinson’s Unity Walk leader
2016 Parkinson’s Unity Walk hopes to raise more than US$1.7m
2 days ago
Pesticides could cause Parkinson’s, research finds
Researchers at a Canadian university have conducted a study that suggests pesticides may lead to Parkinson’s disease. As part of the study, the team used stem cells from people living with Parkinson’s to ascertain whether exposure to pesticides can cause mutations. The scientists leading the study found that neurons exposed to certain pesticides were low in energy and moved less freely. Dr Scott Ryan, professor of molecular and cellular biology at the University of Guelph, Ontario, Canada, said: “People exposed to these chemicals are at about a 250 per cent higher risk of developing Parkinson’s disease than the rest of the population.” Despite the results, the guidelines set for pesticides by many official bodies – including the United States Environmental Protection Agency – do not identify these chemicals as risks. The study concluded that safety guidelines for pesticides may need re-evaluation – and that those living in an agricultural environment…
A study – carried out by researchers from the University of Southern California, Los Angeles, US – has suggested that testing individuals’ tears could provide a cheap way to screen for Parkinson’s. The research found that the tears of those living with Parkinson’s had five times the level of alpha synuclein – a protein molecule that forms toxic clumps and causes nerve damage. It is hoped that the research will lead to early diagnosis of Parkinson’s and help doctors delay the disease. Dr Mark Lew, who led the study, said: “We believe our research is the first to show that tears may be a reliable, inexpensive and non-invasive biological marker of Parkinson’s disease. “And because the Parkinson’s disease process can begin years or decades before symptoms appear, a biological marker like this could be useful in diagnosing, or even treating, the disease earlier.”
€100,000 investment opportunity for central nervous system research
Zcube, a research venture of Italian pharmaceutical company Zambon, has invited researchers, scientists and aspiring entrepreneurs to apply for its third international Open Accelerator programme. The programme – which runs for 12 weeks at the Openzone campus in Milan, Italy – will have a specific focus on the therapeutic areas of the central nervous system and the respiratory system, including rare diseases in these two areas. Upon completing the accelerator, participants will have the chance to win seed investment of up to €100,000 to develop their projects in collaboration with Zambon. Elena Zambon, president of Zambon, said: “Open Accelerator is a fundamental ‘school’ teaching young researchers how to communicate with the business world and venture capitalists and to take their ideas out of the laboratories and let them become effective opportunities to improve patients’ lives.” Submissions for the accelerator programme are open until 30 June 2018.